{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T00:10:34Z","timestamp":1795133434546,"version":"4.10.3"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Cell-free DNA (cfDNA) analysis has advantages over tissue analysis for molecular profiling of classic Hodgkin lymphoma (cHL) at diagnosis and offers additional opportunities for sensitive non-invasive disease tracking during treatment. The aim of this study is to correlate cfDNA based molecular profiling with disease characteristics including serum Thymus and Activation Regulated Chemokine (TARC) levels and FDG-PET imaging, which are established markers of disease assessment. cfDNA isolated from plasma samples of 42 cHL patients was analyzed using low coverage whole genome and targeted next-generation sequencing. Patients were clustered in three groups based on Epstein-Barr virus (EBV) and <jats:italic>SOCS1<\/jats:italic> mutational status. Patients in the EBV-negative (EBV\u2212) &amp; <jats:italic>SOCS1<\/jats:italic> mutated (m) cluster had more extensive disease based on significantly higher serum TARC (sTARC) levels, higher metabolic tumor volume and increased risk of treatment failure. Additionally, the median variant allele frequency and mutational load was highest in the EBV\u2212\u2009&amp; <jats:italic>SOCS1<\/jats:italic>m cluster, which was validated in two external cohorts. The estimated tumor fraction and median variant allele frequency of the single nucleotide variants correlated with sTARC levels. Disease tracking over time demonstrated cfDNA level dynamics that partly resembled sTARC levels and imaging results. In conclusion, we show that cfDNA based clustering on EBV status and <jats:italic>SOCS1<\/jats:italic> mutational status correlates with adverse disease characteristics and increased risk of treatment failure. CfDNA-based disease tracking has the potential to serve as a sensitive tool that can complement existing response assessment methods in cHL patients.<\/jats:p>","DOI":"10.1007\/s00277-025-06328-8","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T19:36:02Z","timestamp":1744140962000},"page":"1789-1800","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Molecular profiling of cell-free DNA from classic Hodgkin lymphoma patients identifies potential prognostic clusters and corresponds with disease dynamics"],"prefix":"10.1007","volume":"104","author":[{"given":"Nick","family":"Veltmaat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geok-Wee","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Teesink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Terpstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Bult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Nijland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Kluiver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"Diepstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter J.","family":"Plattel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"issue":"3","key":"6328_CR1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3390\/diagnostics12030573","volume":"12","author":"G Ingravallo","year":"2022","unstructured":"Ingravallo G, Tamma R, Opinto G, Annese T, Gaudio F, Specchia G et al (2022) The Effect of the Tumor Microenvironment on Lymphoid Neoplasms Derived from B Cells. Diagnostics 12(3):573","journal-title":"Diagnostics"},{"issue":"21","key":"6328_CR2","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2017-06-781989","volume":"130","author":"WR Liu","year":"2017","unstructured":"Liu WR, Shipp MA (2017) Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood 130(21):2265\u201370","journal-title":"Blood"},{"issue":"10","key":"6328_CR3","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.3390\/ijms20102416","volume":"20","author":"D Aldinucci","year":"2019","unstructured":"Aldinucci D, Borghese C, Casagrande N (2019) Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It. Int J Mol Sci 20(10):2416","journal-title":"Int J Mol Sci"},{"issue":"3","key":"6328_CR4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/path.2711","volume":"221","author":"D Aldinucci","year":"2010","unstructured":"Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A (2010) The classical Hodgkin\u2019s lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 221(3):248\u201363","journal-title":"J Pathol"},{"issue":"4","key":"6328_CR5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/hon.2523","volume":"36","author":"G Vera-Lozada","year":"2018","unstructured":"Vera-Lozada G, Segges P, Stefanoff CG, Barros MHM, Niedobitek G, Hassan R (2018) Pathway-focused gene expression profiles and immunohistochemistry detection identify contrasting association of caspase 3 (CASP3) expression with prognosis in pediatric classical Hodgkin lymphoma. Hematol Oncol 36(4):663\u201370","journal-title":"Hematol Oncol"},{"issue":"4","key":"6328_CR6","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3390\/cancers13040682","volume":"13","author":"MM Brune","year":"2021","unstructured":"Brune MM, Juskevicius D, Haslbauer J, Dirnhofer S, Tzankov A (2021) Genomic Landscape of Hodgkin Lymphoma. Cancers 13(4):682","journal-title":"Cancers"},{"issue":"4","key":"6328_CR7","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","volume":"35","author":"MA Weniger","year":"2021","unstructured":"Weniger MA, K\u00fcppers R (2021) Molecular biology of Hodgkin lymphoma. Leukemia 35(4):968\u201381","journal-title":"Leukemia"},{"key":"6328_CR8","doi-asserted-by":"crossref","first-page":"9513701","DOI":"10.1155\/2019\/9513701","volume":"2019","author":"D De Goycoechea","year":"2019","unstructured":"De Goycoechea D, Stalder G, Martins F, Duchosal MA (2019) Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives. J Oncol 2019:9513701","journal-title":"J Oncol"},{"issue":"3","key":"6328_CR9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/blood-2009-12-257345","volume":"116","author":"C Steidl","year":"2010","unstructured":"Steidl C, Telenius A, Shah SP, Farinha P, Barclay L, Boyle M et al (2010) Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood 116(3):418\u201327","journal-title":"Blood"},{"issue":"10","key":"6328_CR10","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T et al (2010) Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma. N Engl J Med 362(10):875\u201385","journal-title":"N Engl J Med"},{"issue":"6","key":"6328_CR11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.blre.2015.06.003","volume":"29","author":"HJA Adams","year":"2015","unstructured":"Adams HJA, Nievelstein RAJ, Kwee TC (2015) Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma. Blood Rev 29(6):417\u201325","journal-title":"Blood Rev"},{"issue":"9","key":"6328_CR12","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/PAS.0000000000000242","volume":"38","author":"D Hollman-Hewgley","year":"2014","unstructured":"Hollman-Hewgley D, Lazare M, Bordwell A, Zebadua E, Tripathi P, Ross AS et al (2014) A single slide multiplex assay for the evaluation of classical Hodgkin lymphoma. Am J Surg Pathol 38(9):1193\u2013202","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"6328_CR13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.15614","volume":"184","author":"H Wang","year":"2019","unstructured":"Wang H, Balakrishna JP, Pittaluga S, Jaffe ES (2019) Diagnosis of Hodgkin lymphoma in the modern era. Br J Haematol 184(1):45\u201359","journal-title":"Br J Haematol"},{"key":"6328_CR14","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","volume":"29","author":"DA Eichenauer","year":"2018","unstructured":"Eichenauer DA, Aleman BMP, Andr\u00e9 M, Federico M, Hutchings M, Illidge T et al (2018) Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv19-29","journal-title":"Ann Oncol"},{"issue":"4","key":"6328_CR15","doi-asserted-by":"crossref","first-page":"322","DOI":"10.6004\/jnccn.2022.0021","volume":"20","author":"RT Hoppe","year":"2020","unstructured":"Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM et al (2020) NCCN Guidelines\u00ae Insights: Hodgkin Lymphoma, Version 2.2022. J Natl Compr Canc Netw 20(4):322\u201334","journal-title":"J Natl Compr Canc Netw"},{"key":"6328_CR16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ctrv.2019.06.002","volume":"77","author":"JM Zaucha","year":"2019","unstructured":"Zaucha JM, Chauvie S, Zaucha R, Biggii A, Gallamini A (2019) The role of PET\/CT in the modern treatment of Hodgkin lymphoma. Cancer Treat Rev 77:44\u201356","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"6328_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000533766","volume":"69","author":"V Tomarchio","year":"2024","unstructured":"Tomarchio V, Rigacci L (2024) Fluorodeoxyglucose-Positron Emission Tomography in Relapsed\/Refractory Hodgkin Lymphoma: A Practical Approach. Chemotherapy 69(1):1\u201310","journal-title":"Chemotherapy"},{"issue":"22","key":"6328_CR18","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.2023020959","volume":"142","author":"A Diepstra","year":"2023","unstructured":"Diepstra A, Nolte IM, van den Berg A, Magpantay LI, Mart\u00ednez-Maza O, Levin LI (2023) Elevated serum TARC levels precede classic Hodgkin lymphoma diagnosis by several years. Blood 142(22):1928\u201331","journal-title":"Blood"},{"issue":"3","key":"6328_CR19","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3324\/haematol.2011.053199","volume":"97","author":"WJ Plattel","year":"2012","unstructured":"Plattel WJ, van den Berg A, Visser L, van der Graaf A, Pruim J, Vos H et al (2012) Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin\u2019s lymphoma. Haematologica 97(3):410\u20135","journal-title":"Haematologica"},{"issue":"1","key":"6328_CR20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjh.16514","volume":"190","author":"WJ Plattel","year":"2020","unstructured":"Plattel WJ, Visser L, Diepstra A, Glaudemans AWJM, Nijland M, van Meerten T et al (2020) Interim thymus and activation regulated chemokine versus interim 18F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation. Br J Haematol 190(1):40\u20134","journal-title":"Br J Haematol"},{"issue":"3","key":"6328_CR21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/his.14836","volume":"82","author":"M Kilsdonk","year":"2023","unstructured":"Kilsdonk M, Veldman C, Rosati S, Plattel W, Diepstra A (2023) The value of thymus and activation related chemokine immunohistochemistry in classic Hodgkin lymphoma diagnostics. Histopathology 82(3):495\u2013503","journal-title":"Histopathology"},{"issue":"12","key":"6328_CR22","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1038\/s41375-022-01717-8","volume":"36","author":"J Driessen","year":"2022","unstructured":"Driessen J, Kersten MJ, Visser L, van den Berg A, Tonino SH, Zijlstra JM et al (2022) Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP. Leukemia 36(12):2853\u201362","journal-title":"Leukemia"},{"issue":"2","key":"6328_CR23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajh.23361","volume":"88","author":"M Sauer","year":"2013","unstructured":"Sauer M, Pl\u00fctschow A, Jachimowicz RD, Kleefisch D, Reiners KS, Ponader S et al (2013) Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am J Hematol 88(2):113\u20135","journal-title":"Am J Hematol"},{"issue":"4","key":"6328_CR24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/jcla.10081","volume":"17","author":"C Li","year":"2003","unstructured":"Li C, Hsu H, Wu T, Tsao K, Sun C, Wu JT (2003) Cell-free DNA is released from tumor cells upon cell death: a study of tissue cultures of tumor cell lines. J Clin Lab Anal 17(4):103\u2013107","journal-title":"J Clin Lab Anal"},{"issue":"5","key":"6328_CR25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.molmed.2020.01.012","volume":"26","author":"E Heitzer","year":"2020","unstructured":"Heitzer E, Auinger L, Speicher MR (2020) Cell-Free DNA and Apoptosis: How Dead Cells Inform About the Living. Trends Mol Med 26(5):519\u201328","journal-title":"Trends Mol Med"},{"key":"6328_CR26","doi-asserted-by":"crossref","first-page":"103166","DOI":"10.1016\/j.critrevonc.2020.103166","volume":"157","author":"Z Hu","year":"2021","unstructured":"Hu Z, Chen H, Long Y, Li P, Gu Y (2021) The main sources of circulating cell-free DNA: Apoptosis, necrosis and active secretion. Crit Rev Oncol Hematol 157:103166","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"6328_CR27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/ph14030207","volume":"14","author":"V Camus","year":"2021","unstructured":"Camus V, Jardin F (2021) Cell-Free DNA for the Management of Classical Hodgkin Lymphoma. Pharmaceuticals 14(3):207","journal-title":"Pharmaceuticals"},{"issue":"8","key":"6328_CR28","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/annonc\/mdp006","volume":"20","author":"S Hohaus","year":"2009","unstructured":"Hohaus S, Giachelia M, Massini G, Mansueto G, Vannata B, Bozzoli V et al (2009) Cell-free circulating DNA in Hodgkin\u2019s and non-Hodgkin\u2019s lymphomas. Ann Oncol 20(8):1408\u201313","journal-title":"Ann Oncol"},{"issue":"1","key":"6328_CR29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3324\/haematol.2019.237719","volume":"106","author":"V Camus","year":"2021","unstructured":"Camus V, Viennot M, Lequesne J, Viailly P, Bohers E, Bessi L et al (2021) Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study. Haematologica 106(1):154\u201362","journal-title":"Haematologica"},{"issue":"224","key":"6328_CR30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6(224):224","journal-title":"Sci Transl Med"},{"issue":"4","key":"6328_CR31","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/1541-7786.MCR-19-0768","volume":"18","author":"KCS Oliveira","year":"2020","unstructured":"Oliveira KCS, Ramos IB, Silva JMC, Barra WF, Riggins GJ, Palande V et al (2020) Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer. Mol Cancer Res 18(4):517\u201328","journal-title":"Mol Cancer Res"},{"issue":"364","key":"6328_CR32","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1126\/scitranslmed.aai8545","volume":"8","author":"F Scherer","year":"2016","unstructured":"Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AFM, Esfahani MS et al (2016) Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med 8(364):364","journal-title":"Sci Transl Med"},{"issue":"2","key":"6328_CR33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S2352-3026(14)00039-8","volume":"2","author":"P Vandenberghe","year":"2015","unstructured":"Vandenberghe P, Wlodarska I, Tousseyn T, Dehaspe L, Dierickx D, Verheecke M et al (2015) Non-invasive detection of genomic imbalances in Hodgkin\/Reed-Sternberg cells in early and advanced stage Hodgkin\u2019s lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. Lancet Haematol 2(2):55","journal-title":"Lancet Haematol"},{"issue":"10","key":"6328_CR34","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.medj.2021.09.002","volume":"2","author":"S Sobesky","year":"2021","unstructured":"Sobesky S, Mammadova L, Cirillo M, Drees EEE, Mattlener J, D\u00f6rr H et al (2021) In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin\u2019s lymphoma and facilitates ultrasensitive residual disease detection. Med 2(10):1171\u20131193","journal-title":"Med"},{"issue":"22","key":"6328_CR35","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","volume":"131","author":"V Spina","year":"2018","unstructured":"Spina V, Bruscaggin A, Cuccaro A, Martini M, Di Trani M, Forestieri G et al (2018) Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 131(22):2413\u201325","journal-title":"Blood"},{"issue":"7","key":"6328_CR36","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBdO, Berti E et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36(7):1720\u201348","journal-title":"Leukemia"},{"key":"6328_CR37","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.csbj.2023.01.023","volume":"21","author":"K Keijzer","year":"2023","unstructured":"Keijzer K, Niezink AGH, De Boer JW, Van Doesum JA, Noordzij W, Van Meerten T et al (2023) Semi-automated 18F-FDG PET segmentation methods for tumor volume determination in Non-Hodgkin lymphoma patients: a literature review, implementation and multi-threshold evaluation. Comput Struct Biotechnol J 21:1102","journal-title":"Comput Struct Biotechnol J"},{"issue":"4","key":"6328_CR38","doi-asserted-by":"crossref","first-page":"e1295202","DOI":"10.1080\/2162402X.2017.1295202","volume":"6","author":"M Nijland","year":"2017","unstructured":"Nijland M, Veenstra RN, Visser L, Xu C, Kushekhar K, Van Imhoff GW et al (2017) HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy? OncoImmunology 6(4):e1295202","journal-title":"OncoImmunology"},{"issue":"1","key":"6328_CR39","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-023-01500-x","volume":"16","author":"N Veltmaat","year":"2023","unstructured":"Veltmaat N, Zhong Y, de Jesus FM, Tan GW, Bult JAA, Terpstra MM et al (2023) Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA. J Hematol Oncol 16(1):104","journal-title":"J Hematol Oncol"},{"key":"6328_CR40","doi-asserted-by":"crossref","unstructured":"M. Vasimuddin, S. Misra, H. Li, S. Aluru. 2019 Efficient Architecture-Aware Acceleration of BWA-MEM for Multicore Systems. 2019 IEEE International Parallel and Distributed Processing Symposium (IPDPS) 2019.","DOI":"10.1109\/IPDPS.2019.00041"},{"issue":"5","key":"6328_CR41","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C et al (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43(5):491\u20138","journal-title":"Nat Genet"},{"issue":"9","key":"6328_CR42","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A et al (2010) The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20(9):1297\u2013303","journal-title":"Genome Res"},{"issue":"7","key":"6328_CR43","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3390\/ph14070617","volume":"14","author":"E Bourbon","year":"2021","unstructured":"Bourbon E, Alcazer V, Cheli E, Huet S, Sujobert P (2021) How to Obtain a High Quality ctDNA in Lymphoma Patients: Preanalytical Tips and Tricks. Pharmaceuticals 14(7):617","journal-title":"Pharmaceuticals"},{"issue":"12","key":"6328_CR44","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1101\/gr.175141.114","volume":"24","author":"I Scheinin","year":"2014","unstructured":"Scheinin I, Sie D, Bengtsson H, van de Wiel MA, Olshen AB, van Thuijl HF et al (2014) DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res 24(12):2022\u201332","journal-title":"Genome Res"},{"issue":"1","key":"6328_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA et al (2017) Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun 8(1):1\u201313","journal-title":"Nat Commun"},{"key":"6328_CR46","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bbacli.2017.03.006","volume":"7","author":"O \u00d8strup","year":"2017","unstructured":"\u00d8strup O, Ahlborn LB, Lassen U, Mau-S\u00f8rensen M, Nielsen FC (2017) Detection of copy number alterations in cell-free tumor DNA from plasma. BBA Clin 7:120\u20136","journal-title":"BBA Clin"},{"issue":"2","key":"6328_CR47","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-21-2291","volume":"28","author":"G Boons","year":"2022","unstructured":"Boons G, Vandamme T, Mari\u00ebn L, Lybaert W, Roeyen G, Rondou T et al (2022) Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up. Clin Cancer Res 28(2):338\u201349","journal-title":"Clin Cancer Res"},{"issue":"3","key":"6328_CR48","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1158\/2643-3230.BCD-22-0128","volume":"4","author":"F Maura","year":"2023","unstructured":"Maura F, Ziccheddu B, Xiang JZ, Bhinder B, Rosiene J, Abascal F et al (2023) Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells. Blood Cancer Discov 4(3):208\u201327","journal-title":"Blood Cancer Discov"},{"issue":"9","key":"6328_CR49","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s00262-012-1255-z","volume":"61","author":"D Mechtcheriakova","year":"2012","unstructured":"Mechtcheriakova D, Svoboda M, Meshcheryakova A, Jensen-Jarolim E (2012) Activation-induced cytidine deaminase (AID) linking immunity, chronic inflammation, and cancer. Cancer Immunol Immunother 61(9):1591\u20138","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"6328_CR50","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1158\/2767-9764.CRC-23-0140","volume":"3","author":"F Gomez","year":"2023","unstructured":"Gomez F, Fisk B, McMichael JF, Mosior M, Foltz JA, Skidmore ZL et al (2023) Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma. Cancer Res Commun 3(11):2312\u201330","journal-title":"Cancer Res Commun"},{"issue":"23","key":"6328_CR51","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1182\/bloodadvances.2019001012","volume":"3","author":"K Wienand","year":"2019","unstructured":"Wienand K, Chapuy B, Stewart C, Dunford AJ, Wu D, Kim J et al (2019) Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. Blood Adv 3(23):4065\u201380","journal-title":"Blood Adv"},{"issue":"12","key":"6328_CR52","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","volume":"39","author":"DM Kurtz","year":"2021","unstructured":"Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ et al (2021) Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol 39(12):1537","journal-title":"Nat Biotechnol"},{"issue":"10","key":"6328_CR53","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/nm.3943","volume":"21","author":"A Ortega-Molina","year":"2015","unstructured":"Ortega-Molina A, Boss IW, Canela A, Pan H, Jiang Y, Zhao C et al (2015) The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat Med 21(10):1199\u2013208","journal-title":"Nat Med"},{"issue":"22","key":"6328_CR54","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","volume":"131","author":"E Tiacci","year":"2018","unstructured":"Tiacci E, Ladewig E, Schiavoni G, Penson A, Fortini E, Pettirossi V et al (2018) Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood 131(22):2454\u201365","journal-title":"Blood"},{"issue":"17","key":"6328_CR55","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.3390\/cancers14174297","volume":"14","author":"M Nohtani","year":"2022","unstructured":"Nohtani M, Vrzalikova K, Ibrahim M, Powell JE, Fennell \u00c9, Morgan S, Grundy R, McCarthy K, Dewberry S, Bouchal J, Bouchalova K (2022) Impact of Tumour Epstein-Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): A Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL. Cancers 14(17):4297","journal-title":"Cancers"},{"issue":"4","key":"6328_CR56","doi-asserted-by":"crossref","first-page":"e6995","DOI":"10.1002\/cam4.6995","volume":"13","author":"F Liu","year":"2024","unstructured":"Liu F, Tian S, Liu Q, Deng Y, He Q, Shi Q et al (2024) Comparison of genomic alterations in Epstein-Barr virus-positive and Epstein-Barr virus-negative diffuse large B-cell lymphoma. Cancer Medicine 13(4):e6995","journal-title":"Cancer Medicine"},{"issue":"7","key":"6328_CR57","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.7150\/ijbs.72534","volume":"18","author":"A Zhang","year":"2022","unstructured":"Zhang A, Miao K, Sun H, Deng C (2022) Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. Int J Biol Sci 18(7):3019\u201333","journal-title":"Int J Biol Sci"},{"issue":"30","key":"6328_CR58","doi-asserted-by":"crossref","first-page":"29097","DOI":"10.18632\/oncotarget.4829","volume":"6","author":"JK Lennerz","year":"2015","unstructured":"Lennerz JK, Hoffmann K, Bubolz A, Lessel D, Welke C, R\u00fcther N et al (2015) Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma. Oncotarget 6(30):29097\u2013110","journal-title":"Oncotarget"},{"issue":"9","key":"6328_CR59","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jmoldx.2022.06.002","volume":"24","author":"J Song","year":"2022","unstructured":"Song J, Kim JY, Kim S, Park Y (2022) Utility of Epstein-Barr Viral Load in Blood for Diagnosing and Predicting Prognosis of Lymphoma: A Comparison with Epstein-Barr Virus-Encoded RNA in Situ Hybridization. J Mol Diagn 24(9):977\u201391","journal-title":"J Mol Diagn"},{"issue":"4","key":"6328_CR60","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1182\/blood.V99.4.1474","volume":"99","author":"JI Mart\u00edn-Subero","year":"2002","unstructured":"Mart\u00edn-Subero JI, Gesk S, Harder L, Sonoki T, Tucker PW, Schlegelberger B et al (2002) Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood 99(4):1474\u20137","journal-title":"Blood"},{"issue":"4","key":"6328_CR61","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood.V99.4.1381","volume":"99","author":"S Joos","year":"2022","unstructured":"Joos S, Menz CK, Wrobel G, Siebert R, Gesk S, Ohl S et al (2022) Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood 99(4):1381\u20137","journal-title":"Blood"},{"issue":"5","key":"6328_CR62","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1532\/IJH97.06048","volume":"83","author":"MA Weniger","year":"2006","unstructured":"Weniger MA, Barth TFE, M\u00f6ller P (2006) Genomic alterations in Hodgkin\u2019s lymphoma. Int J Hematol 83(5):379\u201384","journal-title":"Int J Hematol"},{"issue":"3","key":"6328_CR63","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/pathogens7030059","volume":"7","author":"K Vrzalikova","year":"2018","unstructured":"Vrzalikova K, Sunmonu T, Reynolds G, Murray P (2018) Contribution of Epstein-Barr Virus Latent Proteins to the Pathogenesis of Classical Hodgkin Lymphoma. Pathogens 7(3):59","journal-title":"Pathogens"},{"issue":"6","key":"6328_CR64","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/emboj\/17.6.1700","volume":"17","author":"E Kilger","year":"1998","unstructured":"Kilger E, Kieser A, Baumann M, Hammerschmidt W (1998) Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 17(6):1700\u20139","journal-title":"EMBO J"},{"issue":"3","key":"6328_CR65","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1074-7613(00)80623-8","volume":"9","author":"RG Caldwell","year":"1998","unstructured":"Caldwell RG, Wilson JB, Anderson SJ, Longnecker R (1998) Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9(3):405\u201311","journal-title":"Immunity"},{"issue":"21","key":"6328_CR66","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2017-06-781989","volume":"130","author":"WR Liu","year":"2017","unstructured":"Liu WR, Shipp MA (2017) Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood 130(21):2265\u201370","journal-title":"Blood"},{"issue":"7","key":"6328_CR67","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","volume":"125","author":"J Reichel","year":"2015","unstructured":"Reichel J, Chadburn A, Rubinstein PG, Giulino-Roth L, Tam W, Liu Y et al (2015) Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 125(7):1061\u201372","journal-title":"Blood"},{"issue":"11","key":"6328_CR68","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/leu.2014.201","volume":"28","author":"Y Liu","year":"2014","unstructured":"Liu Y, Abdul Razak FR, Terpstra M, Chan FC, Saber A, Nijland M et al (2014) The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing. Leukemia 28(11):2248","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06328-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06328-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06328-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:10:32Z","timestamp":1745575832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06328-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6328"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06328-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and with the approval of the Medical Ethics Review Board of the University Medical Center Groningen (2018\/437).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was waived for all retrospective patients and obtained for all prospectively included patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}